Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
RAPT Therapeutics ( (RAPT) ) has shared an announcement.
On June 21, 2025, RAPT Therapeutics, Inc. expanded its Board of Directors from five to seven members, appointing Dr. Scott Braunstein and Dr. Ashley Dombkowski as Class III directors. Dr. Braunstein, with over 30 years of experience in the biotechnology and pharmaceutical sectors, joins the Audit Committee, while Dr. Dombkowski, with extensive experience as an executive and investor in the biotechnology field, joins the Nominating and Corporate Governance Committee. This strategic move aims to leverage their expertise to strengthen the company’s governance and operational capabilities.
The most recent analyst rating on (RAPT) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.
Spark’s Take on RAPT Stock
According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.
RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.
To see Spark’s full report on RAPT stock, click here.
More about RAPT Therapeutics
Average Trading Volume: 109,615
Technical Sentiment Signal: Sell
Current Market Cap: $122.9M
For a thorough assessment of RAPT stock, go to TipRanks’ Stock Analysis page.